Biomarker-derived Fast-and-frugal Decision Tree for Preemption Of veno-occlusive Disease/sinusoidal Obstructive Syndrome

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Aug 29

PMID 39207866

Authors

Sophie Paczesny

Iztok Hozo

Benjamin Djulbegovic

Affiliations

Soon will be listed here.

References

Grupp S, Corbacioglu S, Kang H, Teshima T, Khaw S, Locatelli F . Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. Lancet Haematol. 2023; 10(5):e333-e345. DOI: 10.1016/S2352-3026(23)00011-X. View

Djulbegovic B, Hozo I, Lizarraga D, Thomas J, Barbee M, Shah N . Evaluation of a fast-and-frugal clinical decision algorithm ('pathways') on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants. J Eval Clin Pract. 2022; 29(1):3-12. PMC: 9840687. DOI: 10.1111/jep.13780. View

Bajwa R, Mahadeo K, Taragin B, Dvorak C, McArthur J, Jeyapalan A . Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and.... Biol Blood Marrow Transplant. 2017; 23(11):1817-1825. DOI: 10.1016/j.bbmt.2017.07.021. View

Djulbegovic B, Hozo I, Dale W . Transforming clinical practice guidelines and clinical pathways into fast-and-frugal decision trees to improve clinical care strategies. J Eval Clin Pract. 2018; 24(5):1247-1254. DOI: 10.1111/jep.12895. View

Kornblum N, Ayyanar K, Benimetskaya L, Richardson P, Iacobelli M, Stein C . Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006; 16(1):105-14. DOI: 10.1089/oli.2006.16.105. View

Coutsouvelis J, Kirkpatrick C, Dooley M, Spencer A, Kennedy G, Chau M . Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study. Transplant Cell Ther. 2023; 29(6):383.e1-383.e10. DOI: 10.1016/j.jtct.2023.03.014. View

Hozo I, Djulbegovic B . Generalised decision curve analysis for explicit comparison of treatment effects. J Eval Clin Pract. 2023; 29(8):1271-1278. DOI: 10.1111/jep.13915. View

Carreras E . How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2014; 168(4):481-91. DOI: 10.1111/bjh.13215. View

Kernan N, Grupp S, Smith A, Arai S, Triplett B, Antin J . Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018; 181(6):816-827. PMC: 6032999. DOI: 10.1111/bjh.15267. View

10.

Han Y, Bidgoli A, DePriest B, Mendez A, Bijangi-Vishehsaraei K, Perez-Albuerne E . Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation. JCI Insight. 2023; 8(10). PMC: 10322680. DOI: 10.1172/jci.insight.168221. View

11.

Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A . Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012; 379(9823):1301-9. DOI: 10.1016/S0140-6736(11)61938-7. View

12.

Pichler H, Horner K, Engstler G, Poetschger U, Glogova E, Karlhuber S . Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017; 23(7):1128-1133. DOI: 10.1016/j.bbmt.2017.03.022. View

13.

Dalle J, Giralt S . Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Biol Blood Marrow Transplant. 2015; 22(3):400-9. DOI: 10.1016/j.bbmt.2015.09.024. View

14.

Djulbegovic B, Hozo I, Cuker A, Guyatt G . Improving methods of clinical practice guidelines: From guidelines to pathways to fast-and-frugal trees and decision analysis to develop individualised patient care. J Eval Clin Pract. 2023; 30(3):393-402. DOI: 10.1111/jep.13953. View

15.

Djulbegovic B, Hozo I, Mayrhofer T, van den Ende J, Guyatt G . The threshold model revisited. J Eval Clin Pract. 2018; 25(2):186-195. PMC: 6590161. DOI: 10.1111/jep.13091. View

16.

Akil A, Zhang Q, Mumaw C, Raiker N, Yu J, Velez de Mendizabal N . Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(10):1739-45. PMC: 4568166. DOI: 10.1016/j.bbmt.2015.07.004. View

17.

Richardson P, Riches M, Kernan N, Brochstein J, Mineishi S, Termuhlen A . Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016; 127(13):1656-65. PMC: 4817309. DOI: 10.1182/blood-2015-10-676924. View

18.

Bazarbachi A, Al Hamed R, Labopin M, Halaburda K, Labussiere H, Bernasconi P . Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020; 56(4):917-927. DOI: 10.1038/s41409-020-01135-3. View

19.

Hozo I, Djulbegovic B, Luan S, Tsalatsanis A, Gigerenzer G . Towards theory integration: Threshold model as a link between signal detection theory, fast-and-frugal trees and evidence accumulation theory. J Eval Clin Pract. 2015; 23(1):49-65. DOI: 10.1111/jep.12490. View

20.

Richardson P, Corbacioglu S, Ho V, Kernan N, Lehmann L, Maguire C . Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2012; 12(1):123-36. DOI: 10.1517/14740338.2012.749855. View